Ernexa Therapeutics Partners with Cellipont Bioservices to Advance ERNA-101 Cell Therapy for Ovarian Cancer
Key Insights
Ernexa Therapeutics (search) has entered a manufacturing partnership with Cellipont Bioservices (search) to advance ERNA-101, its lead cell therapy for ovarian cancer (search) treatment, toward clinical trials.
ERNA-101 utilizes engineered induced mesenchymal stem cells (search) (iMSCs (search)) derived from iPSCs (search) to reprogram immunologically "cold" tumors into "hot" ones, increasing immune cell infiltration.
Preclinical studies presented at AACR and ASCO meetings demonstrated ERNA-101's potential to suppress tumor growth through enhanced immune system activation.
Ernexa Therapeutics (search) has announced a strategic manufacturing partnership with Cellipont Bioservices (search) to advance ERNA-101, its lead cell therapy candidate for ovarian cancer (search), toward clinical trials. The collaboration will focus on Engineering, Differentiation, and Production (EDP) activities to support the transition from preclinical development to clinical manufacturing.
Novel iMSC Technology Platform
Ernexa's core technology centers on engineering induced pluripotent stem cells (iPSCs (search)) and transforming them into induced mesenchymal stem cells (search) (iMSCs (search)). These iMSCs represent a specialized type of stem cell with a unique ability to migrate toward tumors. The company's allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution that eliminates the need for patient-specific cell harvesting.
ERNA-101 is designed to activate and regulate the immune system's response to recognize and attack cancer cells. According to Sanjeev Luther, President and CEO of Ernexa Therapeutics (search), "This collaboration marks an important milestone in advancing our iMSC platform, which we believe has the potential to reshape the treatment landscape for patients with advanced solid tumors (search)."
Promising Preclinical Results
In preclinical studies presented at this year's AACR and ASCO annual meetings, ERNA-101 demonstrated the potential to reprogram immunologically "cold" tumors into "hot" ones. This transformation increases immune cell infiltration and suppresses tumor growth, addressing a critical challenge in cancer immunotherapy where many tumors evade immune system recognition.
The preclinical data suggests that ERNA-101's mechanism of action could overcome the limitations of current treatments for patients with advanced solid tumors (search), particularly in ovarian cancer (search) where treatment options remain limited.
Manufacturing Partnership Details
Cellipont Bioservices (search), a leading cell therapy Contract Development and Manufacturing Organization (CDMO), will support the current Good Manufacturing Practice (cGMP) development and scale-up of the ERNA-101 manufacturing process. This partnership is crucial for preparing the therapy for upcoming clinical trials.
"We are pleased to collaborate with Ernexa Therapeutics (search) as they advance a bold and highly differentiated approach to treating cancer," said Darren Head, CEO of Cellipont Bioservices (search). "Supporting the development of synthetic, allogeneic iMSC therapies like ERNA-101 aligns with our commitment to enabling scientific innovation through collaborative, high-quality cell therapy manufacturing."
Broader Pipeline Development
Beyond ERNA-101, Ernexa is developing ERNA-201 (search), a cell therapy product designed to target inflammation and treat autoimmune diseases. However, the company's initial focus remains on developing ERNA-101 for ovarian cancer (search) treatment, leveraging the same iMSC platform technology.
Luther emphasized the partnership's significance, stating, "Cellipont brings deep technical capabilities and a shared sense of urgency to help us translate the promise of ERNA-101 into a clinically viable therapy."
The collaboration represents a critical step in Ernexa's progression toward first-in-human trials, with the manufacturing partnership providing the necessary infrastructure and expertise to meet regulatory requirements for clinical development.